View Older Stories View More Recent Stories

Mar 30, 2020 06:09AM AstraZeneca (AZN) Reports FARXIGA Reduced Incidence of Heart Failure Worsening or Cardiovascular Death in Sub-Analysis from Landmark Phase III DAPA-HF Trial
Mar 28, 2020 09:53AM FARXIGA reduced the incidence of heart failure worsening or cardiovascular death in a sub-analysis from landmark Phase III DAPA-HF trial
Mar 12, 2020 05:59AM Merck (MRK), AstraZeneca (AZN) Report Update on Phase 3 GY004 for Cediranib & LYNPARZA (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
Jan 30, 2020 09:00AM Educational Lung Cancer Event Coming to The Villages to Raise Awareness of the State’s High Rate of Lung Cancer
Jan 27, 2020 07:06AM AstraZeneca (AZN) Reports BRILINTA Met Primary Endpoint in Phase III THALES Trial in Stroke
Jan 27, 2020 07:00AM BRILINTA Met Primary Endpoint in the Phase III THALES Trial in Stroke
Jan 27, 2020 05:57AM AbbVie (ABBV), Allergan (AGN) Report Agreements to Divest Brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase)
Jan 27, 2020 01:15AM AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
Jan 8, 2020 08:15AM Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma
Jan 6, 2020 07:16AM AstraZeneca (AZN) Announces FARXIGA Granted FDA Priority Review For Patients With Heart Failure With Reduced Ejection Fraction
Jan 6, 2020 07:00AM FARXIGA Granted FDA Priority Review For Patients With Heart Failure With Reduced Ejection Fraction
Dec 30, 2019 06:55AM LYNPARZA (Olaparib) Approved in the US as a 1st-line Maintenance Treatment of Germline BRCA-mutated Metastatic Pancreatic Cancer
Dec 20, 2019 06:04PM ENHERTU (fam-trastuzumab deruxtecan-nxki) Approved in the US for HER2-Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2 Based Regimens
Dec 19, 2019 09:00AM SK Holdings strengthens partnership with AstraZeneca, a global bio-pharmaceutical company
Dec 17, 2019 02:10PM AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA Recommended by FDA Advisory Committee for First-Line Maintenance Therapy in Germline BRCA-Mutated Metastatic Pancreatic Cancer
Dec 11, 2019 08:09AM AstraZeneca (AZN), Daiichi [Fam]-Trastuzumab Deruxtecan Achieved Tumor Response of 60.9% in Pivotal Phase II HER2-positive Metastatic Breast Cancer Trial
Dec 11, 2019 08:00AM [Fam]-Trastuzumab Deruxtecan Achieved a Tumor Response of 60.9% in Pivotal Phase II HER2-positive Metastatic Breast Cancer Trial
Dec 7, 2019 07:50AM CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia
Dec 5, 2019 06:49AM AstraZeneca (AZN) and Merck (MRK) Announce LYNPARZA Approved in China as First-Line Maintenance Therapy in BRCAm Advanced Ovarian Cancer
Nov 21, 2019 02:54PM CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia
Nov 18, 2019 06:08AM AstraZeneca (AZN) Reports New Data from 5 Additional Analyses of Ph. 3 DAPA-HF Trial Showing FARXIGA (dapagliflozin) Reduced Ejection Fraction in HF Patients
Nov 17, 2019 11:47AM  Subgroup Analysis of TWILIGHT Trial Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Who Underwent PCI Showed BRILINTA Monotherapy Reduced the Risk of Clinically Relevant Bleeding C
Nov 17, 2019 10:45AM Consistent Effects of FARXIGA in Heart Failure Patients With Reduced Ejection Fraction Shown in New Analyses From Landmark Phase III DAPA-HF Trial
Nov 14, 2019 08:00AM AstraZeneca Launches Diabetes Can Break Your Heart
Nov 8, 2019 02:09PM AstraZeneca (AZN) and FibroGen Inc. (FGEN) Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy and No Increased Cardiovascular Risk in Patients with Anemia from Chronic Kidney Diseas
Nov 8, 2019 02:08PM AstraZeneca (AZN) New Data From the Phase III DAPA-HF Trial Showed FARXIGA Reduced the Worsening of Heart Failure or Cardiovascular Death in HFrEF Patients With and Without CKD
Nov 8, 2019 02:02PM Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy and No Increased Cardiovascular Risk in Patients with Anemia from Chronic Kidney Disease Versus Comparators
Nov 8, 2019 02:00PM New Data From the Phase III DAPA-HF Trial Showed FARXIGA Reduced the Worsening of Heart Failure or Cardiovascular Death in HFrEF Patients With and Without Chronic Kidney Disease
Nov 8, 2019 05:55AM AstraZeneca (AZN) Reports Roxadustat Significantly Increased Hemoglobin Levels for Chronic Kidney Disease Patients with Anemia in Phase III OLYMPUS and ROCKIES Trials
Nov 7, 2019 04:35PM Roxadustat Significantly Increased Hemoglobin Levels for Chronic Kidney Disease Patients with Anemia in Phase III OLYMPUS and ROCKIES Trials
Nov 6, 2019 03:18PM AstraZeneca (AZN) Says CALQUENCE Data to Show Improved PFS in Phase III Front-Line Chronic Lymphocytic Leukemia at ASH
Nov 6, 2019 03:16PM CALQUENCE® Data To Show Improved Progression-Free Survival In Phase III Front-Line Chronic Lymphocytic Leukemia At ASH 2019 Annual Meeting
Oct 30, 2019 07:00AM AstraZeneca to Present Pivotal Roxadustat Phase III Data at the American Society of Nephrology Kidney Week 2019
Oct 28, 2019 03:14PM IMFINZI® (durvalumab) and IMFINZI Plus Tremelimumab Delayed Disease Progression in Phase III POSEIDON Trial for 1st-Line Treatment of Stage IV Non-Small Cell Lung Cancer
Oct 21, 2019 07:00AM FARXIGA Approved in the US to Reduce the Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes
Oct 17, 2019 07:01AM AstraZeneca (AZN) Reports Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Oct 17, 2019 07:00AM [Fam-] Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment of Patients With HER2-positive Metastatic Breast Cancer
Oct 7, 2019 07:48AM AstraZeneca Launches Signature STEM Program to Empower Students to Live Healthier Lives and Inspire Future Scientists
Oct 4, 2019 07:00AM FASENRA® (benralizumab) Approved in the US for Self-administration in a New Pre-filled Auto-injector, the FASENRA Pen™
Sep 30, 2019 10:59AM LYNPARZA (olaparib) More Than Doubled the Time Without Radiographic Disease Progression in Patients With BRCA1/2- or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Sep 30, 2019 10:32AM AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA More Than Doubled Median rPFS in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care
Sep 28, 2019 12:48PM TAGRISSO Is the Only 1st-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer to Deliver a Median Overall Survival of More Than Three Years
Sep 28, 2019 12:23PM LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevaciz
Sep 26, 2019 02:53PM BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy in the TWILIGHT Trial
Sep 18, 2019 06:22AM Ironwood Pharma (IRWD), AstraZeneca (AZN) Collaborate in China on LINZESS
Sep 16, 2019 07:32AM AstraZeneca (AZN) Announces FDA Grants Fast Track Designation for FARXIGA in Heart Failur
Sep 16, 2019 07:30AM FDA Grants Fast Track Designation for FARXIGA in Heart Failure
Sep 9, 2019 07:04AM AstraZeneca (AZN) Reports Results from Phase III CASPIAN trial, Showing IMFINZI (durvalumab) Significantly Improved Overall Survival (OS) in Patients with Extensive-SCLC
Sep 9, 2019 07:00AM IMFINZI Is First Immunotherapy to Show Both Significant Survival Benefit and Improved, Durable Responses in Extensive-Stage Small Cell Lung Cancer
Sep 3, 2019 05:53AM AstraZeneca (AZN) Reports Results from Positive Ph. III THEMIS Trial Showing BRILINTA Reduced Risk of Cardiovascular Events
View More Recent Stories View Older Stories